Quarterly report pursuant to Section 13 or 15(d)

Impairment Losses on Investments - Additional Information (Detail)

v2.4.0.6
Impairment Losses on Investments - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 3 Months Ended 3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Mar. 31, 2013
Mar. 31, 2012
Mar. 31, 2013
Nephromics
Jun. 30, 2012
Nephromics
Mar. 31, 2013
ACTGen, Inc.
Other Than Temporary Impairment Losses Recognized [Line Items]              
Percentage of investment in equity interest         16.80%    
Other than temporarily impaired and written off investment $ 0 $ 3,254,000 $ 0 $ 3,254,000 $ 2,400,000   $ 854,000
Net investment under equity method         $ 505,000 $ 505,000